[go: up one dir, main page]

KR880701536A - 마약성 진통제 및 길항제의 경피 흡수용량 단위 및 투여방법 - Google Patents

마약성 진통제 및 길항제의 경피 흡수용량 단위 및 투여방법

Info

Publication number
KR880701536A
KR880701536A KR1019880700481A KR880700481A KR880701536A KR 880701536 A KR880701536 A KR 880701536A KR 1019880700481 A KR1019880700481 A KR 1019880700481A KR 880700481 A KR880700481 A KR 880700481A KR 880701536 A KR880701536 A KR 880701536A
Authority
KR
South Korea
Prior art keywords
polymer matrix
dosage unit
transdermal administration
polymer
administration according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
KR1019880700481A
Other languages
English (en)
Other versions
KR950012181B1 (ko
Inventor
더블유.치엔 이
치앙 친-치
도요 가부지
Original Assignee
원본미기재
루트저스, 더 스테이트 유니버서티 오브 뉴저지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 원본미기재, 루트저스, 더 스테이트 유니버서티 오브 뉴저지 filed Critical 원본미기재
Publication of KR880701536A publication Critical patent/KR880701536A/ko
Application granted granted Critical
Publication of KR950012181B1 publication Critical patent/KR950012181B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F13/00—Bandages or dressings; Absorbent pads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)

Abstract

내용 없음

Description

마약성 진통제 및 길항제의 경피 흡수용량 단위 및 투여방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 피부투과 증진제를 사용하지 않는 중합체 매트릭스 용량단위 중의 각종 하이드로모르폰 함유량(%,W/W)에서 투과속도(mcg/cm2hr)를 예시하는 그래프이다.
제2도는 중합체 매트릭스층이 하이드로모르폰 10%(W/W) 및 일반식 CH3(CH2)nCOOH(여기서 n은 4 내지 6이다)의 피부투과 증진제 10%를 함유하는 용량 단위로부터 투과속도(mcg/cm2hr)를 예시하는 그래프이다.

Claims (21)

  1. (a) 경피적으로 전달되는 약제에 대하여 실질적으로 불투과성인 지지층; 및 (b) 상기 지지층에 고착되어 있으며, 모르피난(mophinan) 마약성 진통제 및 길항성 약제 중에서 선택된, 하나 이상의 유효량의 약제가 그안에 미세 분산되어 있는 중합체 매트릭스 디스크층(상기 중합체는 생물학적으로 허용되며, 경피 흡수를 위해 약제를 투과시키고 ; 상기 약제는 중합체 매트릭스 내에서 안정하고, 동시에 경피적으로 흡수됨으로써 적어도 최소한의 유효 1일 용량을 제공한다)으로 이루어진, 경피 투여용 모르피난 마약성 진통제 또는 길항성 약제 중합체 매트릭스 용량단위.
  2. 제 1 항에 있어서, 중합체 매트릭스층이 그 내부에 하나 이상의 유효량이 피부투과 증진제를 분산된 형태로 함유하고 있는 경피 투여용 중합체 매트릭스 용량단위.
  3. 제 1 항에 있어서, 중합체 매트릭스가 실리콘 중합체 또는 공중합체인 경피 투여용 중합체 매트릭스 용량단위.
  4. 제 3항에 있어서, 실리콘 중합체 또는 공중합체가 메틸 실리콘 중합체 또는 공중합체 또는 메틸비닐실리콘 중합체 또는 공중합체인 경피 투여용 중합체 매트릭스 용량단위.
  5. 제 1 항에 있어서, 중합체 매트릭스 디스크층이 하기 일반식 가교 결합된 폴리실옥산 중합체인 경피 투여용 중합체 매트릭스 용량단위 :
    상기 식에서, R은 탄소수 1내지 7의 알킬 또는 알콕시, 비닐 , 페닐 또는 그의 조합이고;n은 약 100 내지 약 5,000이다.
  6. 제 3 항에 있어서, 매트릭스가 약 10 내지 약 200마이크론의 단면크기를 갖는 미세 분산된 부분으로 이루어진 경피 투여용 중합체 매트릭스 용량단위.
  7. 제 1 항에 있어서, 약제가 하이드로모르폰인 경피 투여용 중합체 매트릭스 용량단위.
  8. 제 7 항에 있어서, 하이드로모르폰이 중합체 매트릭스층내에, 매트릭스 중합체 중량에 기준하여 적어도 약 10중량%의 양으로 적하되어 존재하는 경피 투여용 중합체 매트릭스 용량단위.
  9. 제 7 항에 있어서, 하이드로모르폰이 중합체 매트릭스층내에, 매트릭스 중합체 중량에 기준하여 약 10중량%의 양으로 적하되어 존재하는 경피 투여용 중합체 매트릭스 용량단위.
  10. 제 1 항에 있어서, 적어도 약 1.2mg이 유효량의 약제가 24시간내에 경피적으로 전달되는 경피 투여용 중합체 매트릭스 용량단위.
  11. 제10항에 있어서, 약제가 하이드로모르폰인 경피 투여용 중합체 매트릭스 용량단위.
  12. 제11항에 있어서, 적어도 2.4mg의 하이드로모르폰이 24시간내에 경피적으로 전달되는 경피 투여용 중합체 매트릭스 용량단위.
  13. 제 3항에 있어서, 실리콘 중합체는 가교-결합된 실옥산 중합체이며, 적어도 1.2mg의 하이드로모르폰 약제가 24시간내에 경피적으로 전달되는 경피 투여용 중합체 매트릭스 용량단위.
  14. 제13항에 있어서, 경피적으로 전달된 양이 24시간내에 적어도 2.4mg인 경피 투여용 중합체 매트릭스 용량단위.
  15. 제13항에 있어서, 가교-결합된 실리콘 중합체가 폴리디메틸실옥산인 경피 투여용 중합체 매트릭스 용량단위.
  16. 제13항에 있어서, 가교-결합된 실리콘 중합체가 가교-결합된 메틸비닐 실리콘 중합체인 경피 투여용 중합체 매트릭스 용량단위.
  17. 제13항에 있어서, 매트릭스층에 존재하는 피부투과 증진제가 접착성층 또는 두개의 층에 존재하며 이소프로필미리스테이트, 일반식이 CH3(CH2)nCOOH(여기서, n은 4 내지 16의 정수이다)인 포화 지방산, 일반식이 CH3(CH2)nCH2OH(여기서, n은 4 내지 16의 정수이다)인 포화알콜, 아존, 에틸 카프릴레이트, 헥사메틸렌 라우르아미드, 헥사메틸렌 팔미트아미드, 및 에틸카프렐레이트 및 카프릴 알콜의 혼합물 중에서 선택된 경피 투여용 방출-조절 중합체 매트릭스 용량단위.
  18. 제17항에 있어서, 피부투과 증진제가 아존인 경피 투여용 용량단위.
  19. 제17항에 있어서, 피부투과 증진제가 이소프로필 미리스테이트인 경피 투여용 용량단위.
  20. 제17항에 있어서, 피부투과 증진제가 에틸 카프릴레이트인 경피 투여용 용량단위.
  21. 제17항에 있어서, 피부투과 증진제가 에틸 카프릴레이트 및 카프릴 알콜의 혼합물인 경피 투여용 용량단위.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880700481A 1986-09-03 1987-09-02 마약성 진통제 및 길항제의 경피흡수 용량단위 Expired - Fee Related KR950012181B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US06/903,273 US4806341A (en) 1985-02-25 1986-09-03 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US903,273 1986-09-03
US903273 1986-09-03
PCT/US1987/002198 WO1988001497A1 (en) 1986-09-03 1987-09-02 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration

Publications (2)

Publication Number Publication Date
KR880701536A true KR880701536A (ko) 1988-11-03
KR950012181B1 KR950012181B1 (ko) 1995-10-14

Family

ID=25417212

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880700481A Expired - Fee Related KR950012181B1 (ko) 1986-09-03 1987-09-02 마약성 진통제 및 길항제의 경피흡수 용량단위

Country Status (11)

Country Link
US (1) US4806341A (ko)
EP (1) EP0290482B1 (ko)
JP (1) JPH02500741A (ko)
KR (1) KR950012181B1 (ko)
AT (1) ATE119380T1 (ko)
AU (1) AU628284B2 (ko)
CA (1) CA1309659C (ko)
DE (1) DE3751140T2 (ko)
DK (1) DK175580B1 (ko)
FI (1) FI98887C (ko)
WO (1) WO1988001497A1 (ko)

Families Citing this family (156)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364628A (en) * 1985-05-31 1994-11-15 Sandoz Ltd. Pharmaceutical compositions
US5560922A (en) * 1986-05-30 1996-10-01 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit using a polyacrylate adhesive polymer and process
GB8626098D0 (en) * 1986-10-31 1986-12-03 Euro Celtique Sa Controlled release hydromorphone composition
US4906463A (en) * 1986-12-22 1990-03-06 Cygnus Research Corporation Transdermal drug-delivery composition
US4839174A (en) * 1987-10-05 1989-06-13 Pharmetrix Corporation Novel transdermal nicotine patch
US5026556A (en) * 1988-11-10 1991-06-25 Norwich Eaton Pharmaceuticals, Inc. Compositions for the transdermal delivery of pharmaceutical actives
DE3910543A1 (de) * 1989-04-01 1990-10-11 Lohmann Therapie Syst Lts Transdermales therapeutisches system mit erhoehtem wirkstofffluss und verfahren zu seiner herstellung
US5096715A (en) * 1989-11-20 1992-03-17 Alko Ltd. Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist
US5240711A (en) * 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
DE3939376C1 (ko) * 1989-11-29 1991-05-08 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg, 5450 Neuwied, De
US5069909A (en) * 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
GB9021674D0 (en) * 1990-10-05 1990-11-21 Ethical Pharma Ltd Transdermal device
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
AU3595393A (en) * 1992-01-31 1993-09-01 Cygnus Therapeutic Systems Transdermal administration of buprenorphine in the form of ion pair complexes
US5900250A (en) * 1992-05-13 1999-05-04 Alza Corporation Monoglyceride/lactate ester permeation enhancer for oxybutnin
KR960704578A (ko) * 1993-09-29 1996-10-09 에드워드 엘. 만델 모노글리세리드/락테이트 에스테르 투과 촉진제(Monoglyceride/Lactate Ester Permeation Enhancer)
DE4403709A1 (de) * 1994-02-07 1995-08-10 Lohmann Therapie Syst Lts Pharmazeutische Zusammensetzung zur systemischen transdermalen Verabreichung mit dem Wirkstoff Morphin-6-glucuronid
EP0748629A4 (en) * 1994-03-11 1997-08-20 Sekisui Chemical Co Ltd PERCUTANEOUS ABSORPTION PLATTER COMPRISING A MORPHINE ACID ADDED SALT
JP2819236B2 (ja) * 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
DE4423850A1 (de) * 1994-07-07 1996-01-11 Labtec Gmbh Transdermales therapeutisches System zur Applikation von Naloxon
US5785991A (en) * 1995-06-07 1998-07-28 Alza Corporation Skin permeation enhancer compositions comprising glycerol monolaurate and lauryl acetate
US5733571A (en) * 1995-12-08 1998-03-31 Euro-Celtique, S.A. Transdermal patch for comparative evaluations
JPH1036265A (ja) * 1996-07-19 1998-02-10 Nitto Denko Corp ブプレノルフィン経皮吸収製剤
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
GB9707934D0 (en) * 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
EP1009407B1 (en) 1997-09-04 2004-04-28 Novoneuron, Inc. Noribogaine in the treatment of pain and drug addiction
EP1041988A4 (en) 1997-12-22 2002-03-13 Euro Celtique Sa METHOD FOR PREVENTING ABUSE OF OPIOID DOSES FORMS
ES2412409T3 (es) 1997-12-22 2013-07-11 Euro-Celtique S.A. Forma farmacéutica para dosificación oral que comprende una combinación de un agonista opiáceo y un antagonista opiáceo
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6835194B2 (en) * 1999-03-18 2004-12-28 Durect Corporation Implantable devices and methods for treatment of pain by delivery of fentanyl and fentanyl congeners
WO2000069416A1 (en) * 1999-05-13 2000-11-23 Unihart Corporation Pharmaceutical compositions comprising apocodeine and/or its derivatives
EP1237544A1 (en) * 1999-12-16 2002-09-11 Trident Technologies, LLC System and method for extended delivery of a therapeutic agent with its receptor loading dose
ES2312413T3 (es) 2000-02-08 2009-03-01 Euro-Celtique S.A. Composiciones de liberacion controlada que contienen un agonista y antagonista de opioide.
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE60138706D1 (de) * 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US7074803B2 (en) * 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
PT1307194E (pt) * 2000-07-31 2008-05-27 Nycomed Danmark Aps Composição à base de fentanil para administração nasal
US6569449B1 (en) 2000-11-13 2003-05-27 University Of Kentucky Research Foundation Transdermal delivery of opioid antagonist prodrugs
US6682757B1 (en) 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
US20030065002A1 (en) 2001-05-11 2003-04-03 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
DE60235159D1 (de) 2001-05-22 2010-03-11 Euro Celtique Sa Behälter und verfahren zum abgeben transdermaler dosierungsformen
ATE404193T1 (de) * 2001-06-05 2008-08-15 Ronald Aung-Din Topische migränetherapie
US8329734B2 (en) * 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
WO2003007802A2 (en) * 2001-07-18 2003-01-30 Euro-Celtique, S.A. Pharmaceutical combinations of oxycodone and naloxone
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US20030044458A1 (en) * 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
DK1414451T3 (da) 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
AU2002324624A1 (en) * 2001-08-06 2003-02-24 Euro-Celtique S.A. Sequestered antagonist formulations
US6844438B2 (en) * 2001-08-15 2005-01-18 Mclean Hospital Corporation N-substituted derivatives of morphinan and uses thereof
US7247315B2 (en) * 2001-08-17 2007-07-24 Lavipharm Laboratories Inc. Compositions and medical device for transdermal delivery of a drug and methods of making and using same
US20040033253A1 (en) * 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) * 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
WO2003079945A1 (en) * 2002-03-20 2003-10-02 Euro-Celtique S.A. Method of administering buprenorphine to treat depression
EP1492505B1 (en) 2002-04-05 2015-06-03 Euro-Celtique S.A. Pharmaceutical preparation containing oxycodone and naloxone
DE60336394D1 (de) * 2002-04-23 2011-04-28 Durect Corp Transdermale analgetische systeme mit reduziertem missbrauchspotential
NZ537180A (en) 2002-06-10 2008-03-28 Euro Celtique Sa Disposal systems of transdermal delivery devices to prevent misuse of the active agents contained therein
JP4642467B2 (ja) * 2002-08-20 2011-03-02 ユーロ−セルティーク エス．エイ． 活性剤及び塩並びに副作用物質の遊離塩基形を含む経皮剤形
PT1551372T (pt) * 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc Subunidade de sequestração e composições e métodos relacionados
WO2004039317A2 (en) * 2002-10-25 2004-05-13 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
US20040102476A1 (en) * 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
EP1913938A1 (en) 2002-12-13 2008-04-23 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
PT1572167E (pt) * 2002-12-13 2008-10-03 Euro Celtique Sa Regime posológico de buprenorfina papa analgesia
WO2004054554A1 (en) * 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine to treat pain in sickle cell crisis
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20040202717A1 (en) * 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
MY135852A (en) 2003-04-21 2008-07-31 Euro Celtique Sa Pharmaceutical products
US8790689B2 (en) 2003-04-30 2014-07-29 Purdue Pharma L.P. Tamper resistant transdermal dosage form
NZ542969A (en) * 2003-04-30 2009-09-25 Purdue Pharma Lp Tamper resistant transdermal dosage form comprising an active agent component and an adverse agent component at the distal site of the active agent layer
WO2004105835A2 (en) * 2003-05-22 2004-12-09 Leading Medical Research, L.L.C. Tubular device for insertion into a hollow organ, and method to form same
CA2529528A1 (en) * 2003-06-20 2004-12-29 Ronald Aung-Din Topical therapy for the treatment of migraines, muscle sprains, muscle spasm, spasticity and related conditions
KR20060054346A (ko) * 2003-07-25 2006-05-22 유로-셀띠끄 소시에떼 아노님 수술후 통증의 수술전 치료
US20080020028A1 (en) * 2003-08-20 2008-01-24 Euro-Celtique S.A. Transdermal dosage form comprising an active agent and a salt and a free-base form of an adverse agent
WO2005044243A2 (en) * 2003-10-30 2005-05-19 Alza Corporation Transdermal analgesic systems having reduced abuse potential
EP2074989B1 (en) 2004-02-23 2013-11-20 Euro-Celtique S.A. Abuse resistance opioid transdermal delivery device
EP1604666A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
CA2569958C (en) 2004-06-12 2016-03-22 Jane C. Hirsh Abuse-deterrent drug formulations
JP4824963B2 (ja) * 2004-08-12 2011-11-30 日東電工株式会社 貼付材及び貼付製剤
JP4745747B2 (ja) * 2004-08-12 2011-08-10 日東電工株式会社 フェンタニル含有貼付製剤
DE102004044578A1 (de) 2004-09-13 2006-03-30 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit einer Haftschicht, Verfahren zum Silikonisieren einer Rückschicht des Systems und Verwendung der Rückschicht
US8252320B2 (en) 2004-10-21 2012-08-28 Durect Corporation Transdermal delivery system for sufentanil
NZ582975A (en) 2004-10-21 2011-07-29 Durect Corp Transdermal delivery systems delivering sufentanil
TW200640526A (en) * 2005-02-24 2006-12-01 Alza Corp Transdermal electrotransport drug delivery systems with reduced abuse potential
EP1702558A1 (en) * 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
WO2006124585A2 (en) * 2005-05-13 2006-11-23 Alza Corporation Multilayer drug system for the delivery of galantamine
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
US20070196456A1 (en) * 2005-09-15 2007-08-23 Visible Assets, Inc. Smart patch
WO2007095147A2 (en) * 2006-02-13 2007-08-23 Aveva Drug Delivery Systems Adhesive preparation comprising sufentanil and methods of using the same
US20070259930A1 (en) * 2006-04-10 2007-11-08 Knopp Neurosciences, Inc. Compositions and methods of using r(+) pramipexole
US8518926B2 (en) * 2006-04-10 2013-08-27 Knopp Neurosciences, Inc. Compositions and methods of using (R)-pramipexole
CN101448498B (zh) * 2006-05-16 2011-04-27 诺普神经科学股份有限公司 R(+)和s(-)普拉克索的组合物以及使用该组合物的方法
US20070278289A1 (en) * 2006-05-31 2007-12-06 Toshiba Tec Kabushiki Kaisha Payment adjusting apparatus and program therefor
MX2008016372A (es) * 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
US20080075768A1 (en) * 2006-07-21 2008-03-27 Vaughn Jason M Hydrophobic opioid abuse deterrent delivery system using opioid antagonists
DE102006054731B4 (de) * 2006-11-21 2013-02-28 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System zur Verabreichung des Wirkstoffs Buprenorphin und Verwendung desselben in der Schmerztherapie
US8524695B2 (en) * 2006-12-14 2013-09-03 Knopp Neurosciences, Inc. Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same
CA2681110A1 (en) * 2007-03-14 2008-09-18 Knopp Neurosciences, Inc. Synthesis of chirally purified substituted benzothiazole diamines
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20100151014A1 (en) * 2008-12-16 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
AU2008346870A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
EP2259780A2 (en) * 2008-02-28 2010-12-15 Syntropharma Limited Pharmaceutical composition comprising naltrexone
WO2010005507A1 (en) 2008-06-30 2010-01-14 Afgin Pharma, Llc Topical regional neuro-affective therapy
MY150600A (en) * 2008-07-07 2014-01-30 Euro Celtique Sa Use of opioid antagonists for treating urinary retention
KR20110071064A (ko) * 2008-08-19 2011-06-28 크놉 뉴로사이언시스 인코포레이티드 (ｒ)-프라미펙솔을 사용하는 조성물 및 방법
BRPI1006186A2 (pt) 2009-03-10 2016-08-23 Euro Celtique Sa composições farmaceuticas de liberação imediata compreedendo oxicodona e naloxona
RU2012101792A (ru) * 2009-06-19 2013-07-27 Нопп Ньюросайенсиз, Инк. Композиции и способы для лечения бокового амиотрофического склероза
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US11607407B2 (en) 2010-04-13 2023-03-21 Relmada Therapeutics, Inc. Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
CN103079571A (zh) 2010-07-23 2013-05-01 德莫科斯公司 降伊波加因碱组合物
CN104873455B (zh) 2010-12-22 2023-09-12 普渡制药公司 包覆的抗篡改控制释放剂型
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013034273A1 (en) * 2011-09-05 2013-03-14 Siegfried Ltd. Kit comprising a packaging material and a solid pharmaceutical or nutraceutical product contained in the packaging material
CA2855990A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Sulfate esters of noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US20140363487A1 (en) 2011-12-12 2014-12-11 Purdue Pharma L.P. Transdermal delivery system comprising buprenorphine
WO2013096816A1 (en) 2011-12-22 2013-06-27 Biogen Idec Ma Inc. Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
CA2858820C (en) 2012-01-25 2021-08-17 Demerx, Inc. Synthetic voacangine
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
WO2014105480A1 (en) 2012-12-28 2014-07-03 Teikoku Pharma Usa, Inc. Extended buprenorphine transdermal delivery compositions and methods for using the same
SG11201506064UA (en) 2013-02-05 2015-08-28 Purdue Pharma Lp Tamper resistant pharmaceutical formulations
US9662313B2 (en) 2013-02-28 2017-05-30 Knopp Biosciences Llc Compositions and methods for treating amyotrophic lateral sclerosis in responders
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
WO2014143201A1 (en) 2013-03-15 2014-09-18 Demerx, Inc. Method for noribogaine treatment of addiction in patients on methadone
HUE031662T2 (en) 2013-06-04 2017-07-28 Lts Lohmann Therapie Systeme Ag Transdermal drug delivery system
US9468630B2 (en) 2013-07-12 2016-10-18 Knopp Biosciences Llc Compositions and methods for treating conditions related to increased eosinophils
PL3019167T3 (pl) 2013-07-12 2021-06-14 Knopp Biosciences Llc Leczenie podwyższonych poziomów eozynofili i/lub bazofili
JP2016525138A (ja) 2013-07-23 2016-08-22 ユーロ−セルティーク エス．エイ． 疼痛および腸内ディスバイオシスをもたらす疾患および／または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ
CA2921378A1 (en) 2013-08-13 2015-02-19 Knopp Biosciences Llc Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders
US9763918B2 (en) 2013-08-13 2017-09-19 Knopp Biosciences Llc Compositions and methods for treating chronic urticaria
US9345711B2 (en) 2014-02-18 2016-05-24 Demerx, Inc. Methods for acute and long-term treatment of drug addiction
US9561232B2 (en) 2014-02-18 2017-02-07 Demerx, Inc. Low dose noribogaine for treating nicotine addiction and preventing relapse of nicotine use
US9591978B2 (en) 2014-03-13 2017-03-14 Demerx, Inc. Methods and compositions for pre-screening patients for treatment with noribogaine
US9561233B2 (en) 2014-03-13 2017-02-07 Demerx, Inc. Use of ibogaine for the treatment of pain
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
US9549935B2 (en) 2014-07-14 2017-01-24 Demerx, Inc. Methods and compositions for treating migraines using noribogaine
US9592239B2 (en) 2014-09-12 2017-03-14 Demerx, Inc. Methods and compositions for ibogaine treatment of impulse control disorder, anxiety-related disorders, violence and/or anger, or regulating food intake
JP6464181B2 (ja) * 2014-10-14 2019-02-06 久光製薬株式会社 貼付剤
WO2016086194A1 (en) 2014-11-26 2016-06-02 Demerx, Inc. Methods and compositions for potentiating the action of opioid analgesics using iboga alkaloids
AU2016226267A1 (en) 2015-03-02 2017-09-28 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoids
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3946106A (en) * 1974-10-24 1976-03-23 G. D. Searle & Co. Microsealed pharmaceutical delivery device
BE889926A (fr) * 1980-08-11 1982-02-11 Searle & Co Tampon de nitroglycerine transdermique
US4336243A (en) * 1980-08-11 1982-06-22 G. D. Searle & Co. Transdermal nitroglycerin pad
US4622218A (en) * 1982-05-18 1986-11-11 University Of Florida Testicular-specific drug delivery
US4479932A (en) * 1982-05-18 1984-10-30 University Of Florida Brain-specific drug delivery
US4599342A (en) * 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
ZA856002B (en) * 1984-08-10 1987-04-29 Du Pont Transdermal delivery of opioids
US4626539A (en) * 1984-08-10 1986-12-02 E. I. Dupont De Nemours And Company Trandermal delivery of opioids
US4573995A (en) * 1984-10-09 1986-03-04 Alza Corporation Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4662218A (en) * 1984-11-19 1987-05-05 Hawthorne M Marion Well logging device and method
CA1272445A (en) * 1985-02-25 1990-08-07 Yie W. Chien Transdermal pharmaceutical absorption dosage unit and process of pharmaceutical administration
US4690683A (en) * 1985-07-02 1987-09-01 Rutgers, The State University Of New Jersey Transdermal varapamil delivery device

Also Published As

Publication number Publication date
DK175580B1 (da) 2004-12-13
DK239288D0 (da) 1988-05-03
CA1309659C (en) 1992-11-03
WO1988001497A1 (en) 1988-03-10
EP0290482A1 (en) 1988-11-17
DE3751140D1 (de) 1995-04-13
JPH02500741A (ja) 1990-03-15
FI98887B (fi) 1997-05-30
FI890995A0 (fi) 1989-03-02
KR950012181B1 (ko) 1995-10-14
US4806341A (en) 1989-02-21
FI890995L (fi) 1989-03-02
ATE119380T1 (de) 1995-03-15
EP0290482B1 (en) 1995-03-08
EP0290482A4 (en) 1990-11-28
DK239288A (da) 1988-06-24
FI98887C (fi) 1997-09-10
AU7915087A (en) 1988-03-24
DE3751140T2 (de) 1995-07-20
AU628284B2 (en) 1992-09-17

Similar Documents

Publication Publication Date Title
KR880701536A (ko) 마약성 진통제 및 길항제의 경피 흡수용량 단위 및 투여방법
CA1325381C (en) Laminated composite for transdermal administration of fentanyl
US6572879B1 (en) Formulations for transdermal delivery of pergolide
US5186939A (en) Laminated composite for transdermal administration of fentanyl
US5562917A (en) Transdermal administration of apomorphine
CA1329132C (en) Method for administering the drug deprenyl so as to minimize the danger of side effects
AU660336B2 (en) Device for the transdermal administration of melatonin
US4573995A (en) Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine
US4262003A (en) Method and therapeutic system for administering scopolamine transdermally
US5665378A (en) Transdermal therapeutic formulation
US4690683A (en) Transdermal varapamil delivery device
WO1996019956A9 (en) Transdermal administration of apomorphine
PT94690A (pt) Composicao laminada para a administracao transdermica de lisurida
GB2192539A (en) Topical diclofenac compositions with systemic action
US5492698A (en) Lanoline derivatives as penetration enhancing substances
AU2004210406B2 (en) Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances, and the use thereof
EP0427741B1 (en) Subsaturated transdermal delivery device
KR960021015A (ko) 경피투여용 패취제제
ZA200505629B (en) Transdermal therapeutic system suitable for heat application for promoting the permeation of active substances and the use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20001007

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20011015

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20011015

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000